ZOETIS INC
Zoetis Inc. (ZTS) is a global leader in animal health, developing, manufacturing and commercialising medicines, vaccines and diagnostics for livestock and companion animals. With a market capitalisation of about $64.7bn, the company benefits from steady, recurring demand driven by pet ownership trends, livestock productivity needs and veterinary services growth across developed and emerging markets. Zoetis' strength lies in a diversified product portfolio, a broad geographic footprint and ongoing investment in R&D and targeted acquisitions to expand its pipeline. Investors should note potential advantages — predictable cash flows, margin resilience and dividend capacity — alongside risks such as regulatory scrutiny, pricing pressures, disease outbreaks and currency exposure. Zoetis may suit investors seeking exposure to defensive growth within healthcare, but it is important to assess valuation, portfolio fit and risk tolerance. This information is educational only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future returns.
Why It's Moving
Zoetis Stock Draws Analyst Optimism Amid Pipeline Momentum and Buyback Firepower
- Convertible notes offering of $1.75 billion fuels buybacks into Q1 2026, enhancing shareholder returns and signaling management's confidence in undervalued shares.
- Neogen acquisition bolsters precision animal health tech, supporting expected 4.7% revenue growth and offsetting companion animal challenges.
- Pipeline stars like CYTOPOINT long-acting approval eyed for late 2026, with 2026 free cash flow forecast to surge 21.6% to $2.78 billion.
Zoetis Stock Draws Analyst Optimism Amid Pipeline Momentum and Buyback Firepower
- Convertible notes offering of $1.75 billion fuels buybacks into Q1 2026, enhancing shareholder returns and signaling management's confidence in undervalued shares.
- Neogen acquisition bolsters precision animal health tech, supporting expected 4.7% revenue growth and offsetting companion animal challenges.
- Pipeline stars like CYTOPOINT long-acting approval eyed for late 2026, with 2026 free cash flow forecast to surge 21.6% to $2.78 billion.
When is the next earnings date for ZOETIS INC (ZTS)?
Zoetis (ZTS) is scheduled to report its next earnings on May 7, 2026, before market open, with a conference call at 8:30 a.m. ET. This release will cover first quarter 2026 financial results. Investors should monitor the company's investor relations site for the live webcast and any updates.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Zoetis' stock, which has significant potential to increase in value.
Financial Health
Zoetis is performing well with strong profits, cash flow, and revenue, reflecting healthy demand for its products.
Dividend
Zoetis Inc. offers a below average dividend yield of 1.49%, indicating limited income potential from dividends. If you invested $1000 you would be paid $14.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
APELLIS PHARMACEUTICALS INC
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases.
Baskets Featuring ZTS
Next-Gen Proteins
Looking to invest in the future of food? This carefully selected group of stocks represents companies solving our global protein challenges. From plant-based alternatives to agricultural innovation, these stocks have been thoughtfully chosen by our analysts for their potential in this growing market.
Published: June 17, 2025
Explore BasketPets Are Family
The emotional bond with our furry companions has created a powerful, recession-resistant market. These carefully selected companies provide essential veterinary care, nutrition, and wellness services that pet owners prioritize regardless of economic conditions.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Steady demand drivers
Rising pet ownership and livestock productivity needs can support predictable revenue, though sales can vary with animal health trends and outbreaks.
Global footprint
A wide geographic reach exposes Zoetis to growth in emerging markets, but also brings currency and regulatory risk across regions.
R&D and pipeline
Ongoing investment in R&D and selective acquisitions fuels future products, yet new launches carry execution and approval risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
